Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
| Line item | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Net cash provided by (used in) operating activities | 23,174 | (11,823) |
| Cash flows from investing activities: | ||
| Sale of future royalties, intellectual property, and other assets, net | 48,935 | — |
| Purchases of property and equipment | (252) | (312) |
| Purchases of investments | (80,836) | (157,712) |
| Sales and maturities of investments | 143,222 | 30,500 |
| Proceeds from sale of PRV | — | 150,000 |
| Net cash provided by investing activities | 111,069 | 22,476 |
ITEM 1.FINANCIAL STATEMENTS
FAQ
- What is Zevra Therapeutics, Inc.'s capex?
- Zevra Therapeutics, Inc. (ZVRA) reported capex of $217K in Q2 2026.
- How has Zevra Therapeutics, Inc.'s capex changed year-over-year?
- Zevra Therapeutics, Inc.'s capex increased by 1.9% year-over-year, from $213K to $217K.
- What is the long-term trend for Zevra Therapeutics, Inc.'s capex?
- Over 4 years (2021 to 2025), Zevra Therapeutics, Inc.'s capex has grown at a 70.7% compound annual growth rate (CAGR), from $102K to $866K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Zevra Therapeutics, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude